SCYNEXIS, Inc. is a pharmaceutical company committed to the
discovery, development and commercialization of novel anti-infectives
to address significant unmet therapeutic needs. Our scientists have
extensive experience in the life sciences industry having, together and
individually, been involved in the discovery and development of
innovative medicines over a broad range of therapy areas.
We are developing our lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.